The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 2, 1997, Pages 132-137

  Dreicer, Robert ^a,b   Karwal, Mark W ^a   Midence, Gerardo ^a   Davis, Charles S ^a   Nettleman, Mary ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Cardiotoxicity; Doxorubicin; Radionuclide angiocardiogram

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCINTIANGIOCARDIOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOCARDIOGRAPHY; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA; DOXORUBICIN; FEMALE; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS;

EID: 0030945099     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199704000-00005     Document Type: Article

References (25)

1. Lefrak EA, Pitha J, Roenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32: 302-31.
2. Blum RH, Carter SK. Adriamycin: a new anti-cancer drug with significant clinical activity. Ann Intern Med 1974;80:249-59.
3. Weaver SK, Fulkerson PK, Lewis R, Leier CV. A paucity of chronic electrocardiographic changes with Adriamycin therapy. J Electrocardiol 1978;11:233-8.
4. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1,273 patients. Cancer Treat Rep 1979;63:827-34.
5. Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978;88:168-75.
6. Van Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
7. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72.
8. McKillop JH, Bristow MR, Goris ML, et al. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-56.
9. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-83.
10. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-18.
11. Gibbons RJ. Equilibrium radionuclide angiography. In: Marcus ML, Schelbert RS, Skorton DJ, Wolf GL, eds. Cardiac imaging. Philadelphia: WB Saunders, 1991:1027-42.
12. Steinherz LJ, Yahalom J. Cardiac complications of cancer therapy. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology, 4th ed. Philadelphia: Lippincott, 1993:2370-85.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
15. Riggs CE Jr. Antitumor antibiotics and related compounds. In: Perry MT, ed. The chemotherapy source book. New York: William & Wilkins, 1992:318-58.
16. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981;141:758-63.
17. Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from post-surgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983;52:51-60.
18. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1682-92.
19. Bonadonna G. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 1989;7:1380-97.
20. Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group Phase III study. J Clin Oncol 1990;8:599-607.
21. Muss HB, Case LD, Richards F, et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 1991;25:1342-8.
22. Choi WB, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.
23. Zaret BL, Schwartz PE, Berger HJ, Schwartz RG. Evaluation of doxorubicin cardiotoxicity with radionuclide angiocardiography at rest. Cancer Treat Symp 1984;3:61-6.
24. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607-13.
25. Bristow MR, Lopez MB, Mason JW, et al. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32-41.